3×
Higher incidence and earlier onset in Black adults vs white adults
Overview
Glaucoma is a group of eye diseases characterized by progressive damage to the optic nerve — the cable connecting the eye to the brain — leading to irreversible vision loss and, if untreated, blindness. Primary open-angle glaucoma (POAG) is by far the most common form. Elevated intraocular pressure (IOP above 21 mmHg) is the major modifiable risk factor, though normal-tension glaucoma can occur with IOP in the normal range. Glaucoma is typically painless and asymptomatic in early and moderate stages — peripheral vision is lost first, and patients often do not notice damage until it is severe. Glaucoma is the second leading cause of blindness worldwide and the leading cause of blindness among Black Americans.
How Glaucoma affects Black patients
Black adults develop primary open-angle glaucoma at three times the rate of white adults, develop it approximately 10 years earlier (onset commonly in the 40s rather than 60s), and experience more rapid optic nerve progression. The African American Eye Disease Study (AAEDS) confirmed significantly higher POAG prevalence — 11% in Black adults aged 40+ vs. 3% in white adults — along with higher rates of normal-tension glaucoma. The Baltimore Eye Survey found that glaucoma was four to five times more prevalent in Black adults than white adults in that community sample.
Despite higher disease burden, Black patients face documented barriers to timely glaucoma diagnosis: lower rates of eye care utilization, limited access to ophthalmology specialists, and documented lower rates of prescription adherence to topical drops — partly driven by cost and insurance coverage gaps. The American Academy of Ophthalmology (AAO) recommends comprehensive eye exams every 1–2 years starting at age 40 for Black adults — earlier than the general population recommendation.
Symptoms
- No early symptoms — POAG is painless and asymptomatic in early stages
- Gradual loss of peripheral (side) vision — often not noticed until moderate disease
- Tunnel vision in advanced disease
- Sudden eye pain, headache, nausea, and rapid vision loss (acute angle-closure glaucoma — a medical emergency)
- Halos around lights (can indicate elevated IOP)
- Blurred vision
When to see a doctor
Black adults should begin comprehensive eye exams with IOP measurement and optic nerve evaluation by age 40 and repeat every 1–2 years thereafter, per AAO and NEI guidance — more frequently if IOP is elevated, optic nerve appears suspicious, or family history of glaucoma is present. A family history of glaucoma in a first-degree relative increases lifetime risk approximately 10-fold.
Seek emergency care immediately for sudden severe eye pain, sudden vision loss, nausea associated with eye pain, or halos around lights — these may indicate acute angle-closure glaucoma, a true ophthalmic emergency requiring same-day treatment to prevent permanent vision loss.
Screening
Comprehensive glaucoma screening includes IOP measurement (tonometry), optic nerve head evaluation, visual field testing, and retinal nerve fiber layer thickness measurement by OCT (optical coherence tomography). Corneal thickness (pachymetry) modifies IOP interpretation — thinner corneas are more common in Black adults and are associated with higher true IOP than tonometry suggests. The National Eye Institute and AAO both recommend that Black adults begin routine glaucoma screening at age 40 and continue every 1–4 years depending on risk factors. Those with first-degree relatives with glaucoma or elevated IOP should start earlier.
Treatment overview
The goal of treatment is to halt optic nerve progression by reducing IOP. Prostaglandin analogs (latanoprost, bimatoprost, travoprost) are the most effective and widely used first-line topical drops, given once daily. Beta-blockers (timolol), alpha-2 agonists (brimonidine), and carbonic anhydrase inhibitors (dorzolamide) are second-line or combination agents. Adherence to daily drops is critical — and is a documented gap particularly in Black patients due to cost, access, and regimen complexity. Selective laser trabeculoplasty (SLT) is an office-based laser procedure that lowers IOP comparably to drops in newly diagnosed patients (LiGHT trial) and is increasingly used as first-line therapy to reduce medication burden. Minimally invasive glaucoma surgery (MIGS) options (iStent, Kahook Dual Blade, OMNI) lower IOP with reduced surgical risk compared to traditional surgery. Trabeculectomy or tube shunt surgery is reserved for advanced or refractory disease.
Questions to ask your doctor
Bring this list to your next appointment.
- What is my current IOP, and what is the trend over time?
- What does my optic nerve look like — is there cupping or rim thinning?
- Am I on the most cost-effective drop with the best side-effect profile for me?
- Is selective laser trabeculoplasty (SLT) appropriate as primary treatment or to reduce my drop burden?
- How often do I need visual field testing and OCT to track progression?
- My family member has glaucoma — when should they be screened?
Find a Ophthalmology
Search our directory of verified Black health providers who specialize in ophthalmology.
Browse Ophthalmology providersMedical disclaimer
This content is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. If you are experiencing a medical emergency, call 911 or your local emergency number immediately.